STAAR Surgical Company reported net sales of $76.0 million for the third quarter of 2022, a 30% increase compared to the prior year quarter. ICL sales increased by 33% and ICL unit growth was 40%. Net income was $10.3 million, or $0.21 per diluted share, compared to $6.0 million, or $0.12 per diluted share, for the prior year quarter.
Net sales increased by 30% to $76.0 million, with constant currency net sales up 37% from the prior year quarter.
ICL sales grew by 33% to $72.0 million, with constant currency ICL sales up 39% from the prior year quarter.
ICL unit growth was up 40% from the prior year quarter.
Net income was $0.21 per share, compared to $0.12 per share in the prior year quarter.
STAAR Surgical anticipates total net sales of approximately $285 million for fiscal 2022, which represents $300 million adjusted for constant currency. The fiscal 2022 outlook includes ICL sales of approximately $272 million, representing approximately 28% year over year growth, and Other Products sales of approximately $13 million. For fiscal 2023, the company expects to achieve approximately 30% ICL sales growth, year over year, to approximately $355 million in total company net sales which contemplates limited sales from Other Products.
Analyze how earnings announcements historically affect stock price performance